

Q BioMed Inc.

11:45 11 Sep 2019

Q BioMed, Chemveda to collaborate further on liver cancer treatment

Q BioMed Inc (OTCMKTS:QBIO) and India-based Chemveda Life Sciences have formalized their collaboration on a compound engineered to battle liver cancer.

The companies have been involved in a joint research program since early 2017 to synthesize the compound uttroside-B and study its use for the treatment of liver cancer.

Uttroside-B, is a potent saponin, a type of chemical compound found in Black Nightshade shrub. Obtaining it can be challenging, but Chemveda developed a method to synthesize it.

Now, the plan is to ramp up production and go forward with pre-clinical testing and clinical trials.

READ: Q BioMed, Chemveda Life Sciences achieve potential chemotherapeutic breakthrough in liver cancer

As part of the deal, Q BioMed will pay Chemveda a mix of cash and stock as well as capped royalty on net sales. Chemveda will have first right of refusal and the right to manufacture any products that come out of the collaboration.

"Chemveda has been an excellent partner in this program, both in terms of execution and problem solving," Q BioMed CEO Denis Corin said in a statement. "We look forward to the next phase as we advance this promising molecule and others towards the clinic."

The companies have reason to be optimistic.

A 2016 Scientific Reports study found the compound to be 10 times more effective against the HepG2 liver cancer cell line than the then-only liver cancer drug approved by the US Food and Drug Administration.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security,

Price: 2.25

Market Cap: \$46.88 m

1 Year Share Price Graph



April 2019 October 2019 April 2020

Share Information

Code: QBIO

Listing: OTCQB

52 week	High	Low
	3.75	0.3401

Sector: Medical technology & services

Website: qbiomed.com

Company Synopsis:

Q BioMed Inc. (OTCQB: QBIO) is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued and under-appreciated biomedical assets. QBIO is dedicated to providing these target assets, the strategic resources, developmental support, and expansion capital to ensure they meet their potential.

action@proactiveinvestors.com

portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand (\$25,000) dollars.